Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Analysts estimate that Pfizer will report an earnings per share (EPS) of $0.58. The market awaits Pfizer's announcement, with ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Recent discussions on X about Pfizer's stock, ticker PFE, have centered around the company's stagnant performance and lack of significant catalysts to drive growth. Many users have expressed ...